Share
The newsletter Danish Pharmacovigilance Update
The newsletter Danish Pharmacovigilance Update puts focus on medicine and its side effects.
The purpose of Danish Pharmacovigilance Update is to give primarily doctors quick and easy access to the most important information about medicine and side effects.
The medicines in focus will be products that are subject to stricter reporting requirements, medicines used by particularly many people, or medicines which for any reason need special attention.
We hope that Danish Pharmacovigilance Update will make it clearer how Danish adverse reaction reports are used by the Danish Health and Medicines Authority and how they form part of joint efforts through our international cooperation.
Danish Pharmacovigilance Update is a monthly electronic newsletter.
-
25 April 2013 /News - miscellaneous
-
25 April 2013 /News - miscellaneous
Danish Pharmacovigilance Update, 21 March 2013
In this issue of Danish Pharmacovigilance Update: Depressive and suicidal thoughts following discontinuation of varenicline (Champix®).
-
25 April 2013 /News - miscellaneous
Danish Pharmacovigilance Update, 21 February 2013
In this issue of Danish Pharmacovigilance Update: Cardiovascular monitoring when initiating and re-initiating treatment with fingolimod (Gilenya®).
-
26 March 2013 /News - miscellaneous
Danish Pharmacovigilance Update, 17 January 2013
In this issue of Danish Pharmacovigilance Update: The Pharmacovigilance Risk Assessment Committee, PRAC, finds that the risks outweigh the benefits from the use of Tredaptive®
-
17 January 2013 /News - miscellaneous
Danish Pharmacovigilance Update, 20 December 2012
In this issue of Danish Pharmacovigilance Update: The Danish Health and Medicines Authority encourages doctors to be aware of suspected long-term adverse reactions from the use of SSRIs in children and adolescents.
-
17 January 2013 /News - miscellaneous
Danish Pharmacovigilance Update, 15 November 2012
In this issue of Danish Pharmacovigilance Update: Chlorhexidine and the risk of anaphylactic reaction.
-
15 November 2012 /News - miscellaneous
Danish Pharmacovigilance Update, 18 October 2012
In this issue of Danish Pharmacovigilance Update, read about: Risk of developing hepatotoxicity in patients undergoing treatment with agomelatine (Valdoxan®)
-
17 October 2012 /News - miscellaneous
Danish Pharmacovigilance Update, 20 September 2012
Among the topics covered in this issue of Danish Pharmacovigilance Update are: New definition of adverse reactions due to new European legislation on pharmacovigilance.
-
06 September 2012 /News - miscellaneous
Danish Pharmacovigilance Update, 16 August 2012
Among the topics covered in this issue of Danish Pharmacovigilance Update are: Maximum single dose of intravenous ondansetron (Zofran® and others) now restricted to 16 mg.
-
03 August 2012 /News - miscellaneous
Danish Pharmacovigilance Update, 21 June 2012
Among the topics covered in this issue of Danish Pharmacovigilance Update are: Decrease in the number of intoxications and suicide attempts using drugs containing acetylsalicylic acid or paracetamol.
-
31 July 2012 /News - miscellaneous
Danish Pharmacovigilance Update, 24 May 2012
Among the topics covered in this issue of Danish Pharmacovigilance Update are: Drug Analysis Prints involving data from more than 14,000 Danish adverse reaction reports available at the Danish Health and Medicines Authority’s website.
-
04 July 2012 /News - miscellaneous
Danish Pharmacovigilance Update, 19 April 2012
Among the topics covered in this issue of Danish Pharmacovigilance Update are: Split and crushed tablets containing finasteride may pose a risk for pregnant and fertile women.
-
19 June 2012 /News - miscellaneous
Danish Pharmacovigilance Update, 15 March 2012
Among the topics covered in this issue of Danish Pharmacovigilance Update are: A new registry study has investigated the frequency of malformations in newborns after treating the mother with antidepressants (SSRI) during the pregnancy.
-
05 March 2012 /News - miscellaneous
Danish Pharmacovigilance Update, 16 February 2012
Among the topics covered in this issue of Danish Pharmacovigilance Update are: Risk of overdose with methotrexate in the treatment of rheumatoid arthritis as well as intensified monitoring of heart rate and blood pressure in connection with treatment with Gilenya.
-
26 January 2012 /News - miscellaneous
Danish Pharmacovigilance Update, 19 January 2012
In this issue of Danish Pharmacovigilance Update read about the risk that patients treated with statins develop diabetes, and proton-pump inhibitors (PPI) and the risk of hypomagnesaemia with long-term use.
-
03 January 2012 /News - miscellaneous
Danish Pharmacovigilance Update, 15 December 2011
Among the topics covered in this issue of Danish Pharmacovigilance Update are: Atomoxetine (Strattera®) and the risk of increased blood pressure and heart rate, increased suspicion of risk of congenital malformations with the antiepileptic topiramate (Topimax® and others), and new recommendations for the antidepressant escitalopram.
-
01 December 2011 /News - miscellaneous
Danish Pharmacovigilance Update, 17 November 2011
In this issue of Danish Pharmacovigilance Update, you can read about domperidone (Motilium® etc.) and potential risk of cardiac disorders, about the European Medicines Agency's recommendation on a lower dose of the antidepressant citalopram as well as about more interesting aspects of pharmacovigilance.
-
09 November 2011 /News - miscellaneous
Danish Pharmacovigilance Update, 20 October 2011
In this edition of Danish Pharmacovigilance Update, you can read about: Use of medicines involving a risk of serious and life-threatening skin reactions, the European Medicines Agency to investigate the possible connection between orlistat and rare cases of severe liver toxicity, and the EMA’s review of peritoneal dialysis solutions from Baxter A/S.
-
26 September 2011 /News - miscellaneous
Danish Pharmacovigilance Update, 15 September 2011
In this issue of Danish Pharmacovigilance Update, read about a significant increase in off-label use of AeroBec® in children under the age of five, and much more.
-
09 September 2011 /News - miscellaneous
Danish Pharmacovigilance Update, 18 August 2011
Among the topics covered in this issue are Vimpat® 15mg/ml syrup (lacosamide) for treatment of epilepsy, which is recalled due to a quality defect and Nplate® (romiplostim), which could increase the risk of disease progression in patients with myelodysplastic syndrome (MDS).
